Shenzhen Kaifa Technology
920029
Shanghai Yongli Belting
300230
Guomai Culture & Media
301052
4
WuHan Hvsen Biotechnology
300871
5
CHANGFU CO.,LTD
871396
US Stock MarketDetailed Quotes
ARTV Artiva Biotherapeutics
- 3.160
- -0.380-10.73%
Close Mar 28 16:00 ET
- 3.160
- 0.0000.00%
Post 16:01 ET
76.99MMarket Cap-1.17P/E (TTM)
3.650High3.150Low80.34KVolume3.510Open3.540Pre Close264.48KTurnover1.83%Turnover RatioLossP/E (Static)24.36MShares17.31052wk High0.41P/B13.89MFloat Cap3.15052wk Low--Dividend TTM4.40MShs Float17.310Historical High--Div YieldTTM14.12%Amplitude3.150Historical Low3.292Avg Price1Lot Size
Artiva Biotherapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -16.03%-55.03M | -37.24%-14.65M | -8.03%-11.61M | -16.33%-13.69M | -5.92%-15.09M | 6.69%-47.43M | -10.68M | -10.75M | -11.76M | -47.38%-14.24M |
| Net income from continuing operations | -127.62%-65.37M | -34.15%-16.1M | -254.91%-17.47M | -58.13%-17.84M | 16.47%-13.96M | 51.15%-28.72M | ---12M | --11.28M | ---11.28M | -37.88%-16.72M |
| Operating gains losses | 408.77%3.6M | --0 | --977K | --2.35M | --268K | --707K | ---- | ---- | ---- | ---- |
| Depreciation and amortization | 7.28%2.43M | 3.37%614K | 12.77%627K | 12.08%603K | 1.56%587K | 95.68%2.27M | --594K | --556K | --538K | 246.11%578K |
| Change In working capital | 98.85%-325K | 71.39%-311K | 112.65%3.01M | 99.80%-7K | -4,812.50%-3.02M | -631.51%-28.28M | ---1.09M | ---23.8M | ---3.46M | -93.11%64K |
| -Change in receivables | 230.63%1.61M | -67.66%555K | 231.26%760K | 116.91%262K | 104.26%35K | -2,064.91%-1.23M | --1.72M | ---579K | ---1.55M | -9.89%-822K |
| -Change in prepaid assets | -480.81%-1.97M | -19.27%176K | -94.43%-1.5M | -77.39%296K | -291.63%-936K | 167.54%516K | --218K | ---772K | --1.31M | 72.14%-239K |
| -Change in payables and accrued expense | 89.39%-140K | 39.63%-1.07M | 210.19%3.81M | 53.74%-681K | -411.22%-2.19M | -114.63%-1.32M | ---1.78M | --1.23M | ---1.47M | -77.83%704K |
| -Change in other current assets | -10.07%125K | -31.11%31K | 3.23%32K | 3.33%31K | -6.06%31K | 214.88%139K | --45K | --31K | --30K | --33K |
| -Change in other working capital | 100.16%43K | 100.08%1K | 99.63%-88K | 104.78%85K | -88.40%45K | -1,007.05%-26.38M | ---1.29M | ---23.7M | ---1.78M | 160.53%388K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -16.03%-55.03M | -37.24%-14.65M | -8.03%-11.61M | -16.33%-13.69M | -5.92%-15.09M | 6.69%-47.43M | ---10.68M | ---10.75M | ---11.76M | -47.38%-14.24M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -363.77%-120.46M | 63.79%-966K | -26,396.55%-130.63M | 106.44%1.35M | 625.35%9.78M | -312.37%-25.98M | -2.67M | -493K | -20.95M | -209.30%-1.86M |
| Net PPE purchase and sale | 80.29%-642K | 89.94%-64K | 46.37%-96K | 20.14%-464K | 99.03%-18K | 48.28%-3.26M | ---636K | ---179K | ---581K | -209.30%-1.86M |
| Net investment purchase and sale | -427.45%-119.82M | 55.61%-902K | -41,470.70%-130.53M | 108.90%1.81M | --9.8M | ---22.72M | ---2.03M | ---314K | ---20.37M | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -363.77%-120.46M | 63.79%-966K | -26,396.55%-130.63M | 106.44%1.35M | 625.35%9.78M | -312.37%-25.98M | ---2.67M | ---493K | ---20.95M | -209.30%-1.86M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 565.11%162.23M | -103.12%-30K | 599.38%163.87M | -16,260.00%-1.62M | 0 | 2,029.67%24.39M | 962K | 23.43M | 10K | 96.07%-12K |
| Net issuance payments of debt | ---149K | ---33K | ---38K | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Net common stock issuance | 1,352,800.00%162.32M | ---4.18M | --166.51M | --0 | --0 | -140.00%-12K | --0 | --0 | --0 | ---12K |
| Proceeds from stock option exercised by employees | 410.00%51K | --23K | --6K | ---- | ---- | -96.99%10K | --0 | --0 | ---- | ---- |
| Net other financing activities | ---- | ---- | ---2.6M | ---- | ---- | 1,633.19%24.39M | --962K | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 565.11%162.23M | -103.12%-30K | 599.38%163.87M | -16,260.00%-1.62M | --0 | 2,029.67%24.39M | --962K | --23.43M | --10K | 96.07%-12K |
| Net cash flow | ||||||||||
| Beginning cash position | -47.69%53.76M | -15.12%56.14M | -36.04%34.51M | -44.08%48.46M | -47.69%53.76M | -36.23%102.78M | --66.14M | --53.95M | --86.66M | -36.23%102.78M |
| Current changes in cash | 72.93%-13.27M | -26.37%-15.65M | 77.47%21.63M | 57.34%-13.95M | 67.09%-5.3M | 16.06%-49.01M | ---12.38M | --12.19M | ---32.71M | -52.46%-16.12M |
| End cash Position | -24.68%40.49M | -24.68%40.49M | -15.12%56.14M | -36.04%34.51M | -44.08%48.46M | -47.69%53.76M | --53.76M | --66.14M | --53.95M | -42.46%86.66M |
| Free cash flow | -9.84%-55.67M | -30.09%-14.71M | -7.14%-11.71M | -14.61%-14.15M | 6.22%-15.1M | 11.27%-50.69M | ---11.31M | ---10.93M | ---12.35M | -56.88%-16.11M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Market Insights
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025